Cabozantinib is an approved treatment for metastatic renal cell carcinoma (mRCC). This report presents an analysis of the safety profile and efficacy of cabozantinib in an unselected population from Poland.
Patients with mRCC, who had been treated with at least 1 previous agent targeting the vascular endothelial growth factor pathway, were eligible to receive cabozantinib at a once-daily dose of 60 mg orally, according to the Managed Access Program (MAP). Data were collected in 4 Polish centers. Patients who had received ≥ 1 dose of cabozantinib were monitored for adverse events (AEs) using Common Terminology Criteria for Adverse Events (CTCAE) v.4.0.
A total of 115 patients were enrolled between October 2016 and March 2018, including 50% with bone metastases, 10% with brain metastases and 4.3% with non-clear-cell RCC; 76% had received ≥ 2 lines of therapy. The median time of follow-up was 12.6 months (95% confidence interval [CI], 11.5-14.1 months). The most common grade 3 and 4 AEs were fatigue (23%), hand-foot syndrome (12%), and diarrhea (10%). Only 4% of patients discontinued treatment owing to AEs, and there were no treatment-related deaths. Partial response was observed in 19% of patients, whereas 56% had stable disease. The median progression-free survival was 12.5 months (95% CI, 9.2-14.2 months), with a 12-month overall survival rate of 70.4% (95% CI, 60.2%-78.5%).
Cabozantinib demonstrated acceptable tolerability and activity in a large unselected population of patients with mRCC under clinical conditions.
Clinical genitourinary cancer. 2019 Feb 20 [Epub ahead of print]
Lubomir Bodnar, Anna Kopczyńska, Jakub Żołnierek, Magdalena Wieczorek-Rutkowska, Paweł Chrom, Piotr Tomczak
Department of Oncology, Military Institute of Medicine, Warsaw, Poland. Electronic address: ., University Hospital of Lord's Transfiguration, Poznan, Poland., Department of Clinical Oncology and Chemotherapy, Magodent Hospital Elbląska, Warsaw, Poland., Regional Oncology Centre in Gdańsk, Copernicus CO, Gdańsk, Poland., Department of Oncology, Military Institute of Medicine, Warsaw, Poland., Clinical Hospital Number 1 of Poznan University of Medical Sciences, Poznan, Poland.